back to US directory
us clinical guidance

Atopic dermatitis across the lifespan

Current AAD topical, systemic and pediatric principles for diagnosing atopic dermatitis, restoring the skin barrier, controlling inflammation and escalating safely.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team · Clinical editorial review · reviewed 2026-08-20 · due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Children, adolescents and adults with atopic dermatitis. Contact dermatitis, scabies, cutaneous T-cell lymphoma, immunodeficiency, primary ichthyosis and other mimics require diagnosis-specific work-up. Drug selection and FDA age indications differ substantially between pediatric and adult patients.
sources for this section:AAD atopic dermatitis 2023–2026

The Bottom Line

  • Make a clinical diagnosis from compatible morphology, distribution, chronic or relapsing itch and age-specific pattern, while actively reconsidering contact allergy, infection and another dermatosis when the course is atypical.
  • Use regular moisturization and gentle skin care for every severity; add an anti-inflammatory topical treatment matched to site, age, severity and skin-barrier condition rather than relying on emollient treatment alone during an inflammatory flare.
  • AAD strongly recommends topical corticosteroids, topical calcineurin inhibitors and indicated topical PDE-4 or JAK inhibitors; bathing and wet-wrap therapy have conditional roles in selected patients.
  • For moderate to severe disease inadequately controlled with optimized topical care, consider phototherapy or an FDA-labeled systemic option through a structured specialist pathway; the 2025 focused update added strong adult recommendations for tapinarof, roflumilast, lebrikizumab and nemolizumab with topical therapy.
  • Avoid routine systemic corticosteroids for chronic atopic dermatitis because the AAD recommends against them; treatment must also address sleep, school or work, mental health and associated allergic disease.
sources for this section:AAD atopic dermatitis 2023–2026

Practical clinical workflow

1
Document itch, sleep loss, flares, body sites, treatment quantity and technique, infection history, exposures, occupational effect and quality of life; examine the entire skin including face, folds, hands and signs of excoriation or lichenification.
2
Create a written skin-care plan covering fragrance-free moisturizer, bathing, cleansers, topical anti-inflammatory potency by body site and the difference between active-flare and maintenance treatment.
3
Demonstrate topical quantity and application, address steroid fear without minimizing genuine site- and potency-related risk, and use a steroid-sparing agent where repeated treatment of sensitive skin is needed.
4
Reassess diagnosis, adherence, quantity, contact allergens and infection before escalation. Patch testing or dermatology review is appropriate when allergic contact dermatitis or another mimic remains plausible.
5
Before systemic treatment, quantify disease and life impact, review vaccines, infection and comorbidity, then follow the exact FDA label and monitoring plan for the selected agent with a defined response review.
sources for this section:AAD atopic dermatitis 2023–2026

Safety boundaries and escalation

  • Painful monomorphic vesicles, punched-out erosions, fever or eye-area involvement can indicate eczema herpeticum and requires same-day antiviral and ophthalmic or acute-care assessment.
  • Rapid spreading erythema, tenderness, purulence or systemic illness needs assessment for bacterial infection; the AAD recommends against routine topical antimicrobials or antiseptics for noninfected disease.
  • Facial, eyelid, genital and flexural skin is more vulnerable to topical-corticosteroid harm; use site-appropriate potency and duration and arrange review when repeated control is required.
  • Biologics and oral JAK inhibitors have materially different infection, thrombosis, malignancy, laboratory, pregnancy and vaccination precautions; a class name is not a monitoring protocol.
sources for this section:AAD atopic dermatitis 2023–2026

Localization

Use the current AAD adult and pediatric guidance together with the selected product’s FDA label. The AAD portal was directly rechecked on 2026-08-20 and includes the 2025 focused adult update and pediatric guidance; recheck the live portal at every scheduled review.
sources for this section:AAD atopic dermatitis 2023–2026

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American Academy of DermatologyAtopic dermatitis clinical guidelineCurrent AAD portal checked 2026-08-20; includes adult topical and systemic guidance, the 2025 focused update and pediatric guidance · accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page’s provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what—if anything—you may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.